Good afternoon :)
Switch to
Place Order

Thyrocare Technologies Ltd

THYROCARE
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹6,079 cr, stock is ranked 443
Moderate RiskStock is 2.43x as volatile as Nifty
1,149.1026.35 (-2.24%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹6,079 cr, stock is ranked 443
Moderate RiskStock is 2.43x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
53.73
PB RatioPB Ratio
14.23
Dividend YieldDiv. Yield
2.17%
Sector PESector PE
38.41
Sector PBSector PB
5.12
Sector Div YldSctr Div Yld
0.68%

Forecast & RatingsDetailed Forecast 

50%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Thyrocare Technologies Limited is a diagnostic chain company which offers a range of medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases.

Investor PresentationView older 

Aug 13, 2021

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

2018201920202021379.32413.52441.44507.0593.2885.1488.40113.15
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has increased by 5.07%

High Pledged Promoter Holding
Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Reply to Clarification Sought 
Announced OnOct 12, 2021

THYROCARE: The Exchange had sought clarification from Thyrocare Technologies Limited with respect to announcement dated 07-Oct-2021, regarding appointment of Dr. Dhaval Rajesh Shah as an additional director of the company at its board meeting held on October 06, 2021. On basis of above the Company was required to clarify following: 1. Confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018.The response of the Company is attached. | Download

THYROCARE: The Exchange had sought clarification from Thyrocare Technologies Limited with respect to announcement dated 07-Oct-2021, regarding appointment of Dr. Dhaval Rajesh Shah as an additional director of the company at its board meeting held on October 06, 2021. On basis of above the Company was required to clarify following: 1. Confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018.The response of the Company is attached. | Download

Clarification 
Announced OnOct 8, 2021
THYROCARE: The Exchange has sought clarification from Thyrocare Technologies Limited with respect to announcement dated 07-Oct-2021, regarding appointment of Dr. Dhaval Rajesh Shah as an additional director of the company at its board meeting held on October 06, 2021. On basis of above the Company is required to clarify following: 1. Confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018.The response of the Company is awaited.
THYROCARE: The Exchange has sought clarification from Thyrocare Technologies Limited with respect to announcement dated 07-Oct-2021, regarding appointment of Dr. Dhaval Rajesh Shah as an additional director of the company at its board meeting held on October 06, 2021. On basis of above the Company is required to clarify following: 1. Confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018.The response of the Company is awaited.
Cash Dividend 
Ex. DateJun 17, 2021

Final • Div/Share: ₹ 15

See all events